
A primate lost to science for nearly a century is still alive.
Local rescuers documented more than 90 Bangka slow lorises—and returned 86 to protected forest.
Every serving. No expiration date. Page 2 of 5.

Local rescuers documented more than 90 Bangka slow lorises—and returned 86 to protected forest.

In an ongoing trial, nearly three-quarters had not needed the usual treatments after a median of more than two years.

In trials, 24% met treatment-stopping criteria versus none on placebo; 19% stayed controlled 24 weeks after stopping all therapy.

Native plants now shelter fish, pollinators and nesting birds in the middle of the city.

The long pattern—not one day's reading—may help clinicians spot who needs earlier attention.

NASA's newly launched space telescope has cleared an early commissioning test with more optical precision than its requirement demanded.

A brief tissue bridge moved helpful algae within three days—and recovery continued after the corals were separated.

Six hospitals changed everyday anesthesia practice, lowering estimated emissions and anesthetic spending without worsening tracked outcomes.

The study will test whether clearing amyloid, then adding a second mechanism, can delay inherited Alzheimer's.

A new alliance is coordinating five years of targeted recovery funding.

Reported malaria deaths fell from 3,259 in 2011 to 52 in 2025.

A randomized trial found continuous glucose monitoring added about five hours a day in the target range—even without insulin.

An EMA committee recommended a once-daily oral RAS inhibitor for eligible adults with metastatic pancreatic cancer.

Forty-four, from the brink.

The future changed 2.2 million times.

Eight complete responses. Twelve patients.

A 32-person study found less injury and fewer symptoms—but it is still early.

A monitor improved when patients could explain what its sensors got wrong.

A new WHO review says transmission now remains only in the remote cross-border Yanomami Focus Area shared by Brazil and Venezuela.

In the OPTIMA extension, adults who stayed on Pasatru had no new lesions detected between weeks 56 and 84; the placebo group had nine.

More than 7.86 million people have been screened. Diagnosis reached 92.4%, treatment 92.7%, and treatment in key high-risk groups 95%.

The national average rose above one tonne per hectare in 2025–26; some farmer-field-school groups reached 1.4 to 2 tonnes while cutting pest treatments.

A preclinical formulation held onto its biological activity for more than two months at 37°C—and matched fresh material in mouse immune-response tests.

The lower dose met the trial’s main goal over 52 weeks. The higher dose did not, and the detailed results are not yet published.